News
EyePoint Pharmaceuticals completes enrollment for the LUCIA trial, advancing DURAVYU's potential as a new treatment for wet AMD.
Opus Genetics partners with the Global RDH12 Alliance to advance gene therapy for inherited retinal disease, aiming for FDA application by late 2025.
Panelists discuss how geographic atrophy (GA) presentations show clinical variability across patients while remaining consistently progressive, requiring a combination of imaging modalities including ...
Panelists discuss how conversations with patients with geographic atrophy have evolved to emphasize the urgency of early intervention, with clinicians now able to offer hope through available ...
Data from the TEASE-3 and SAGA clinical studies of investigational oral gildeuretinol will be presented during the American Society of Retina Specialists (ASRS) 43rd Annual Scientific Meeting being ...
EYLUXV, a new biosimilar for treating serious eye conditions, gains positive EMA recommendation, promising improved patient access and outcomes.
In preparation for the American Society of Retina Specialist (ASRS) annual meeting being held in Long Beach, California, Modern Retina spoke with Gaurav Shah MD, FASRS, Program Chair of the 2025 event ...
Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal care to improve patient outcomes.
Due to the changing regulatory landscape, developing and distinguishing new investigational products from approved treatment options is challenging. That is why advances in treatments, especially in ...
Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results